Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors.
Delombaerde D, Vulsteke C, Van de Veire N, Vervloet D, Moerman V, Van Calster L, Willems AM, Croes L, Gremonprez F, De Meulenaere A, Elzo Kraemer X, Wouters K, Peeters M, Prenen H, De Sutter J. Delombaerde D, et al. Among authors: vulsteke c. Pharmaceuticals (Basel). 2024 Jul 21;17(7):965. doi: 10.3390/ph17070965. Pharmaceuticals (Basel). 2024. PMID: 39065813 Free PMC article.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Free PMC article. Clinical Trial.
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H. Vulsteke C, et al. Breast Cancer Res Treat. 2014 Oct;147(3):557-70. doi: 10.1007/s10549-014-3105-5. Epub 2014 Aug 29. Breast Cancer Res Treat. 2014. PMID: 25168315 Clinical Trial.
SARS-CoV-2 and cancer: Are they really partners in crime?
van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, Papadimitriou K, Altintas S, Vermorken J, Vulsteke C, Janssens A, Berneman Z, Prenen H, Meuris L, Vanden Berghe W, Smits E, Peeters M. van Dam PA, et al. Among authors: vulsteke c. Cancer Treat Rev. 2020 Sep;89:102068. doi: 10.1016/j.ctrv.2020.102068. Epub 2020 Jul 11. Cancer Treat Rev. 2020. PMID: 32731090 Free PMC article. Review.
Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
van Dam P, Huizing M, Roelant E, Hotterbeekx A, De Winter FHR, Kumar-Singh S, Moons P, Amajoud Z, Vulsteke C, Croes L, Janssens A, Berneman Z, Prenen H, Meuris L, Vanden Berghe W, Smits E, Peeters M. van Dam P, et al. Among authors: vulsteke c. Eur J Cancer. 2021 May;148:328-339. doi: 10.1016/j.ejca.2021.02.024. Epub 2021 Feb 27. Eur J Cancer. 2021. PMID: 33773276 Free PMC article.
Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients.
De Winter FHR, Hotterbeekx A, Huizing MT, Konnova A, Fransen E, Jongers B, Jairam RK, Van Averbeke V, Moons P, Roelant E, Le Blon D, Vanden Berghe W, Janssens A, Lybaert W, Croes L, Vulsteke C, Malhotra-Kumar S, Goossens H, Berneman Z, Peeters M, van Dam PA, Kumar-Singh S. De Winter FHR, et al. Among authors: vulsteke c. Cancers (Basel). 2021 Nov 15;13(22):5718. doi: 10.3390/cancers13225718. Cancers (Basel). 2021. PMID: 34830872 Free PMC article.
POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients.
Velasco-Ruiz A, Nuñez-Torres R, Pita G, Wildiers H, Lambrechts D, Hatse S, Delombaerde D, Van Brussel T, Alonso MR, Alvarez N, Herraez B, Vulsteke C, Zamora P, Lopez-Fernandez T, Gonzalez-Neira A. Velasco-Ruiz A, et al. Among authors: vulsteke c. Pharmaceutics. 2021 Nov 16;13(11):1942. doi: 10.3390/pharmaceutics13111942. Pharmaceutics. 2021. PMID: 34834357 Free PMC article.
59 results